RootPath的核心技术优势，在于其功能强大的新靶点发现平台。 该平台能提供包括单细胞分析、肿瘤诊断和免疫治疗在内的多项服务，覆盖众多当前 ...

（中国-广州）呈源生物（RootPath）今天宣布在中国推出基因合成领域的创新性产品 -呈源定制基因库，以序列验证后的单个质粒（plasmid）作为交付 ...

1月6日，生物科技公司RootPath宣布完成1100万美元A轮融资。本轮融资由由经纬中国、元禾原点共同领投。 作为本轮领投方，经纬中国董事总经理喻志云 ...

联系电话：4009950930 关注呈源生物（RootPath）公众号 关于呈源生物 呈源生物（RootPath）是一家专注于基因合成和解码免疫系统的合成生物学和细胞 ...

合成生物学与基因细胞治疗公司呈源生物（RootPath）近日完成近5000万美元B轮融资，本轮融资由云九资本、鼎晖投资共同领投，弘毅生命科学基金跟投 ...

RootPath Custom Gene Library was launched in China earlier this year and was met with broad enthusiasm. RootPath has already commercially delivered thousands of genes to its early-adopter customers.

RootPath offers a range of plasmid vectors, including standard vectors like pUC19, pET-11a, as well as customer-provided ones. Currently, standard RootPath Custom Gene Library supports gene ...

RootPath was incubated and founded by Nest.bio Ventures in 2017 and has since raised more than $60 million from renowned investors such as Sequoia Capital China, CDH Investment and Sky9 Capital.

Article ‘Count’ and ‘Share’ for Rootpath - China based on listed parameters only. The articles listed below published by authors from Rootpath - China, organized by journal and article ...

RootPath was launched by Nest.Bio Ventures in 2017 and has raised $18M in seed and Series A financing. RootPath is located in Cambridge, MA with additional research activities at two sites in China.

RootPath Genomics, a Cambridge, Mass.-based startup developing a T-cell therapy platform for the diagnosis and treatment of cancer, has raised $7 million in seed funding.